$RHHBY news
The latest RHHBY stock news: headlines, filings, AI summaries and sentiment for $RHHBY, updated around the clock.
- Proximal Ventures Raises $27.5 Million Debut Fund to Invest in AI-Driven Drug Development Services
- Madrigal Pharmaceuticals Achieves First Profitable Quarter Driven by Rezdiffra Sales Growth
- FDA Grants 510(k) Clearance to Roche's cobas eplex Respiratory Pathogen Panel
- PTC Therapeutics Reports Record Q3 2026 Revenue and Raises Full-Year Guidance
- Alnylam Pharmaceuticals Reports Q3 2026 Revenue Growth Driven by TTR Franchise
- Chugai Pharmaceutical Reports Q3 2026 GAAP EPS of ¥228.07 and Revenue of ¥1,068B
- ESMO Congress Highlights Oncology Breakthroughs Amid Market Volatility and Fed Uncertainty
- Roche Q3 Revenue Exceeds Expectations Despite Slight Miss in Pharmaceutical Sales
- Roche Pauses Investments in Germany Amid Healthcare Reforms
- Roche Enters into $1.16 Billion Licensing Agreement with China's Rona Therapeutics for Obesity Drug
- Roche's Experimental Eye Drug Shows Vision Improvements in Clinical Trials
- FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Stage III dMMR Colon Cancer
- Alector Announces Licensing Agreement for Parkinson's Treatment Program
- Genentech's Gazyva approved for idiopathic nephrotic syndrome
- Roche partners with Atavistik Bio for allosteric drug discovery in CVRM diseases
- Merck's Remigromig Shows Efficacy for Diabetic Macular Edema in Trial
- Roche and Ionis Report Positive Late-Stage Trial Results for Kidney Drug
- Roche's GLP-1/GIP Agonist Enicepatide Shows 16% Weight Loss in Mid-Stage Trial
- Sandoz Receives Canadian Approval for Generic Ozempic and Biosimilar Licensing Deal
- BioNTech Terminates Colorectal Cancer Vaccine Trial Amid Efficacy Concerns
- Investors Scrutinize Novartis' M&A Strategy After Drug Trial Setbacks
- Exelixis Stock Falls After FDA Delays Approval of New Colon Cancer Treatment
- OraSure Reports First Profit in Years Amid Operational Improvements but Faces Growth Challenges
- Ionis Pharmaceuticals' Sell-Off Was Overdone Despite Clinical Setbacks
- Ionis Pharmaceuticals' Sell-Off Was Overdone Despite Clinical Setbacks
- Arcturus and Moderna Stocks Drop Following BioNTech's Cancer Vaccine Trial Halt